Poor Outcomes of Girdlestone Resection Arthroplasty in Injection Drug Users: A Retrospective Study

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Aug 29

PMID 39200082

Authors

Henry T Shu

Diane Ghanem

Oscar Covarrubias

Zaid Elsabbagh

Alice J Hughes

Rachel B Sotsky

Janet D Conway

Jamie Ferguson

Greg M Osgood

Babar Shafiq

Affiliations

Soon will be listed here.

Abstract

This retrospective cohort study aims to investigate the clinical outcomes of Girdlestone resection arthroplasty (GRA) in injection drug users with septic hip arthritis. Patients who underwent primary GRA for septic hip arthritis secondary to injection drug use at two academic trauma centers from 2015 to 2023 were retrospectively reviewed. Patient demographics, surgical details, and follow-up outcomes, including patient-reported outcome measures, were collected and analyzed. The cohort included 15 patients, with a mean age of 44 ± 11 years and a mean follow-up period of 25 ± 20 months. Among the 15 patients, overall mortality was 27%, and only 4 patients underwent total hip arthroplasty (THA) following GRA. Infection resolution rates were significantly higher in patients who received an antibiotic spacer (75% vs. 0%, = 0.048). GRA in injection drug users is associated with high mortality and low conversion rates to THA. The use of an antibiotic spacer during GRA significantly improves infection resolution rates. Larger studies are required to determine the optimal management strategies for this patient population.

References

Breivik H, Borchgrevink P, Allen S, Rosseland L, Romundstad L, Hals E . Assessment of pain. Br J Anaesth. 2008; 101(1):17-24. DOI: 10.1093/bja/aen103. View

Condell R, Low L, Kearns S, Murphy C . Girdlestone resection arthroplasty of the hip (GRA): a case series-outdated procedure or acceptable outcome?. Eur J Orthop Surg Traumatol. 2023; 34(3):1711-1715. DOI: 10.1007/s00590-023-03793-7. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

Park D, Oh S, Cano M, Salas-Wright C, Vaughn M . Trends and distinct profiles of persons who inject drugs in the United States, 2015-2019. Prev Med. 2022; 164:107289. DOI: 10.1016/j.ypmed.2022.107289. View

Hser Y, Evans E, Grella C, Ling W, Anglin D . Long-term course of opioid addiction. Harv Rev Psychiatry. 2015; 23(2):76-89. DOI: 10.1097/HRP.0000000000000052. View

Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S . Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023; 11(5):e659-e672. DOI: 10.1016/S2214-109X(23)00057-8. View

Li H, Rombach I, Zambellas R, Walker A, McNally M, Atkins B . Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med. 2019; 380(5):425-436. PMC: 6522347. DOI: 10.1056/NEJMoa1710926. View

Devlin N, Brooks R . EQ-5D and the EuroQol Group: Past, Present and Future. Appl Health Econ Health Policy. 2017; 15(2):127-137. PMC: 5343080. DOI: 10.1007/s40258-017-0310-5. View

Shah N, Parker M . What is the outcome after a Girdlestone resection arthroplasty following a hip fracture?. Hip Int. 2022; 33(5):948-951. DOI: 10.1177/11207000221126135. View

10.

Ballard W, Lowry D, Brand R . Resection arthroplasty of the hip. J Arthroplasty. 1995; 10(6):772-9. DOI: 10.1016/s0883-5403(05)80073-7. View

11.

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

12.

Sawadogo M, Kafando H, Ouedraogo S, Korsaga A, Ouedraogo S, Tinto S . Is Head and Neck Resection of the Femur (Girdlestone's Procedure) Still Relevant? Indications and Results About 24 Cases. Open Orthop J. 2018; 12:69-74. PMC: 5842383. DOI: 10.2174/1874325001812010069. View

13.

Bradley H, Hall E, Asher A, Furukawa N, Jones C, Shealey J . Estimated Number of People Who Inject Drugs in the United States. Clin Infect Dis. 2022; 76(1):96-102. PMC: 10202436. DOI: 10.1093/cid/ciac543. View

14.

Vincenten C, Gosens T, van Susante J, Somford M . The Girdlestone situation: a historical essay. J Bone Jt Infect. 2019; 4(5):203-208. PMC: 6831807. DOI: 10.7150/jbji.36618. View

15.

Humphrey T, Tatara A, Bedair H, Alpaugh K, Melnic C, Nelson S . Rates and Outcomes of Periprosthetic Joint Infection in Persons Who Inject Drugs. J Arthroplasty. 2022; 38(1):152-157. PMC: 9979100. DOI: 10.1016/j.arth.2022.07.018. View

16.

Nazemi A, Upfill-Brown A, Arshi A, Sekimura T, Zeegen E, McPherson E . Analysis of perioperative outcomes in hip resection arthroplasty. Arch Orthop Trauma Surg. 2021; 142(9):2139-2146. DOI: 10.1007/s00402-021-03833-z. View

17.

Basu I, Howes M, Jowett C, Levack B . Girdlestones excision arthroplasty: current update. Int J Surg. 2011; 9(4):310-3. DOI: 10.1016/j.ijsu.2011.01.012. View

18.

Clark R, Baxter J, Aweh G, OConnell E, Fisher W, Barton B . Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. J Subst Abuse Treat. 2015; 57:75-80. PMC: 4560989. DOI: 10.1016/j.jsat.2015.05.001. View

19.

Dawson J, Fitzpatrick R, Carr A, Murray D . Questionnaire on the perceptions of patients about total hip replacement. J Bone Joint Surg Br. 1996; 78(2):185-90. View

20.

Castellanos J, Flores X, Llusa M, Chiriboga C, Navarro A . The Girdlestone pseudarthrosis in the treatment of infected hip replacements. Int Orthop. 1998; 22(3):178-81. PMC: 3619587. DOI: 10.1007/s002640050236. View